Program
fexuprazan
Also written as “DWP14012”, “DWP14012 20mg” and “DWP14012 40mg”.
Its studies are mostly in Esophagitis · Gastroesophageal Reflux · Stomach Ulcer · Peptic Ulcer · Non-Erosive Reflux Disease, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Daewoong Pharmaceutical | 285 open or running | phase 4since Apr 8, 2026 | Mar 16, 2016 | Dec 2027phase 4 · NCT07533266 |
| GlaxoSmithKline | 10 open or running | phase 1since Dec 15, 2011 | Dec 15, 2011 | none ahead |
Also a collaborator on its studies: shanghai-haini-pharmaceutical-co-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 14 studies since Dec 15, 2011.
- Oct 28, 2020No phase study in Erosive EsophagitisDaewoong Pharmaceutical · NCT04613895 · 186 enrolled · Korea, Republic of
- Mar 3, 2021Phase 3 study in Peptic UlcerDaewoong Pharmaceutical · NCT04784910 · 423 enrolled · Korea, Republic of
- Mar 25, 2021Phase 1 study in HealthyDaewoong Pharmaceutical · NCT04827472 · 36 enrolled · Korea, Republic of
- Dec 15, 2021Phase 1 study in Healthy VolunteersDaewoong Pharmaceutical · NCT06508645 · 33 enrolled · South Korea
- Mar 16, 2022Phase 1 study in Drug Drug InteractionDaewoong Pharmaceutical · NCT05304845 · 24 enrolled · Korea, Republic of
- Sep 4, 2022Phase 1 study in Drug Drug InteractionDaewoong Pharmaceutical · NCT05574374 · 36 enrolled · Korea, Republic of
- Nov 14, 2022Phase 1 study in Drug Drug InteractionDaewoong Pharmaceutical · NCT05812404 · 36 enrolled · Korea, Republic of
- Apr 2, 2023Phase 3 study in Esophagitis, PepticDaewoong Pharmaceutical · NCT05813561 · 332 enrolled · China
- Apr 7, 2023Phase 1 study in Phase 1 Study, Healthy VolunteersDaewoong Pharmaceutical · NCT05868967 · 8 enrolled · China
- Oct 16, 2023Phase 3 study in Non-Erosive Reflux DiseaseDaewoong Pharmaceutical · NCT06121830 · 324 planned · Korea, Republic of
- May 13, 2024Phase 1 study in Erosive Gastroesophageal Reflux DiseaseDaewoong Pharmaceutical · NCT06437951 · 40 enrolled
- Dec 20, 2024Phase 3 study in Helicobacter Pylori InfectionDaewoong Pharmaceutical · NCT06751121 · 461 enrolled · South Korea
- Apr 8, 2026Phase 4 study in NSAID (Non-Steroidal Anti-Inflammatory Drug)Daewoong Pharmaceutical · NCT07533266 · 360 planned · South Korea
- Jul 1, 20262 phase 3 studiesDaewoong Pharmaceutical · NCT07730138, NCT07746518
Ahead
- Dec 2027Primary completion: phase 4 study in NSAID (Non-Steroidal Anti-Inflammatory Drug)Daewoong Pharmaceutical · NCT07533266
- Apr 15, 2028Primary completion: phase 3 study in Stomach UlcerDaewoong Pharmaceutical · NCT07730138
- Aug 2029Primary completion: phase 3 study in Healed Erosive EsophagitisDaewoong Pharmaceutical · NCT07746518
TargetBeta
“Potassium-transporting ATPase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Esomeprazolerule | AstraZeneca | phase 4 | 129 |
| Rabeprazolerule | Eisai | phase 4 | 66 |
| Omeprazolerule | AstraZeneca | phase 4 | 56 |
| tegoprazanrule | HK inno.N | phase 4 | 48 |
| vonoprazanrule | Takeda | phase 4 | 48 |
Studies
All 29 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07746518Healed Erosive Esophagitis | 3 | Not yet recruiting | Daewoong Pharmaceutical | Aug 2029 | 420 |
| NCT07730138Stomach Ulcer · Indonesia, South Korea | 3 | Not yet recruiting | Daewoong Pharmaceutical | Apr 15, 2028 | 384 |
| NCT07533266NSAID (Non-Steroidal Anti-Inflammatory Drug) · South Korea | 4 | Not yet recruiting | Daewoong Pharmaceutical | Dec 2027 | 360 |
| NCT06751121Helicobacter Pylori Infection · South Korea | 3 | Completed | Daewoong Pharmaceutical | Apr 24, 2025 | 461 |
| NCT06437951Erosive Gastroesophageal Reflux Disease | 1 | UNKNOWN | Daewoong Pharmaceutical | Jan 2025 | 40 |
| NCT06121830Non-Erosive Reflux Disease · Korea, Republic of | 3 | Recruiting | Daewoong Pharmaceutical | Jan 2025 | 324 |
| NCT05868967Phase 1 Study, Healthy Volunteers · China | 1 | Active, not recruiting | Daewoong Pharmaceutical | May 31, 2023 | 8 |
| NCT05813561Esophagitis, Peptic · China | 3 | Completed | Daewoong Pharmaceutical | Jul 23, 2022 | 332 |
| NCT05812404Drug Drug Interaction · Korea, Republic of | 1 | UNKNOWN | Daewoong Pharmaceutical | Mar 28, 2023 | 36 |
| NCT05574374Drug Drug Interaction · Korea, Republic of | 1 | Completed | Daewoong Pharmaceutical | Mar 6, 2023 | 36 |
| NCT05304845Drug Drug Interaction · Korea, Republic of | 1 | Completed | Daewoong Pharmaceutical | May 22, 2022 | 24 |
| NCT06508645Healthy Volunteers · South Korea | 1 | Completed | Daewoong Pharmaceutical | Mar 29, 2022 | 33 |
| NCT04827472Healthy · Korea, Republic of | 1 | UNKNOWN | Daewoong Pharmaceutical | Jun 30, 2021 | 36 |
| NCT04784910Peptic Ulcer · Korea, Republic of | 3 | Completed | Daewoong Pharmaceutical | Nov 27, 2023 | 423 |
| NCT04613895Erosive Esophagitis · Korea, Republic of | – | UNKNOWN | Daewoong Pharmaceutical | May 30, 2021 | 186 |
| NCT04490434Healthy Male Volunteers · Korea, Republic of | 1 | UNKNOWN | Daewoong Pharmaceutical | Aug 31, 2020 | 110 |
| NCT04341454Acute Gastritis · Korea, Republic of | 3 | Completed | Daewoong Pharmaceutical | Aug 4, 2021 | 327 |
| NCT04341428Healed Erosive Esophagitis · Korea, Republic of | 3 | UNKNOWN | Daewoong Pharmaceutical | Aug 30, 2021 | 406 |
| NCT04328766Drug-drug Interaction · Australia | 1 | Completed | Daewoong Pharmaceutical | Nov 21, 2020 | 36 |
| NCT04185805Healthy · Korea, Republic of | 1 | UNKNOWN | Daewoong Pharmaceutical | Feb 28, 2020 | 24 |
| NCT04167267Healthy · Korea, Republic of | 1 | UNKNOWN | Daewoong Pharmaceutical | Dec 2019 | 24 |
| NCT04003441Healthy · Korea, Republic of | 1 | UNKNOWN | Daewoong Pharmaceutical | Aug 2019 | 24 |
| NCT03811080Non-Erosive Gastroesophageal Reflux Disease · Korea, Republic of | 3 | UNKNOWN | Daewoong Pharmaceutical | Feb 2020 | 327 |
| NCT03736369Erosive Esophagitis · Korea, Republic of | 3 | Completed | Daewoong Pharmaceutical | Aug 7, 2019 | 263 |
| NCT03574415Healthy Volunteers · Korea, Republic of | 1 | Completed | Daewoong Pharmaceutical | Jan 18, 2019 | 80 |
| NCT03487562Healthy · Korea, Republic of | 1 | Completed | Daewoong Pharmaceutical | Jan 11, 2019 | 48 |
| NCT03184324Erosive Gastroesophageal Reflux Disease · Korea, Republic of | 2 | Completed | Daewoong Pharmaceutical | Apr 18, 2018 | 211 |
| NCT02757144Healthy · Korea, Republic of | 1 | Completed | Daewoong Pharmaceutical | Feb 2017 | 120 |
| NCT01495026Prostatic Hyperplasia · Australia | 1 | Completed | GlaxoSmithKline | Apr 3, 2012 | 63 |
How it is read
Names in the registry
- “DWP14012”, 10 entries
- “DWP14012 20mg”, 3 entries
- “DWP14012 40mg”, 3 entries
- “DWP14012 tablet A”, 3 entries
- “DWP14012 tablet B”, 3 entries
Conditions, from the studies’ own filings
- Esophagitis, 4 studies
- Gastroesophageal Reflux, 3 studies
- Stomach Ulcer, 1 study
- Peptic Ulcer, 1 study
- Non-Erosive Reflux Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.